Oruka Therapeutics received a Strong Buy rating following positive interim results from its phase 2a trial of ORKA-001, a drug targeting moderate-to-severe plaque psoriasis. The drug uses a half-life extension technology aiming for once-yearly dosing, which could offer best-in-class efficacy and stand out in a competitive biologics market. Key upcoming milestones include longer-term phase 2a data expected in the second half of 2026 and phase 2b dose-finding results in 2027. The company currently holds strong liquidity with $479.7 million in cash but may need to raise additional capital within the next year to support operations and pipeline development.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
Crypto investigator ZachXBT criticized all current hardware wallets as insecure and unreliable for signing transactions or storing significant funds. He highlighted Ledger as particularly problematic due to frequent updates that disrupt basic functio...
